Biogen adds patent for multiple sclerosis drug Tecfidera

03/20/2013 | Reuters

Biogen Idec obtained a new patent for its multiple sclerosis drug Tecfidera, which could receive FDA approval this month. The patent on a daily dosing regimen of 480 milligrams is due to expire in 2028.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA